Research · 2 min read
AI Drug Discovery Moves Into the Clinic: What One Phase 2a Trial Shows, and Which Numbers Still Need Checking
Insilico Medicine's generative AI-designed TNIK inhibitor rentosertib completed a randomised phase 2a trial in idiopathic pulmonary fibrosis, published in Nature Medicine; phase, indication and efficacy figures still have to come from the paper and the trial registry.